Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ayca Nazli Mogol"'
Autor:
Ayca Nazli Mogol, Qianying Zuo, Jin Young Yoo, Alanna Zoe Kaminsky, Ozan Berk Imir, Yosef Landesman, Christopher J Walker, Zeynep Madak Erdogan
Publikováno v:
Endocrinology.
Approximately 70% of human breast cancers express estrogen receptor-α (ERα), providing a potential target for endocrine therapy. However, 30%–40% of patients with ER+ breast cancer still experiences recurrence and metastasis, with a 5-year relati
Autor:
Zeynep Madak Erdogan, Debu Tripathy, Akshara Singareeka Raghavendra, John D. O'Neill, Evelyn Aranda, Benita S. Katzenellenbogen, Yvonne Ziegler, Ben Ho Park, David J. Shapiro, Nicole Hwajin Park, Eylem Kulkoyluoglu-Cotul, Ozan Berk Imir, Jenny Drnevich, Christine Chien, Ashlie Santaliz Casiano, Yu-Jeh Liu, Ayca Nazli Mogol, Qianying Zuo
Supplementary Table from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08fcbd670914710b64958120b07b5ee2
https://doi.org/10.1158/1541-7786.22528229.v1
https://doi.org/10.1158/1541-7786.22528229.v1
Autor:
Zeynep Madak Erdogan, Debu Tripathy, Akshara Singareeka Raghavendra, John D. O'Neill, Evelyn Aranda, Benita S. Katzenellenbogen, Yvonne Ziegler, Ben Ho Park, David J. Shapiro, Nicole Hwajin Park, Eylem Kulkoyluoglu-Cotul, Ozan Berk Imir, Jenny Drnevich, Christine Chien, Ashlie Santaliz Casiano, Yu-Jeh Liu, Ayca Nazli Mogol, Qianying Zuo
Estrogen receptor–positive (ER+) metastatic tumors contribute to nearly 70% of breast cancer–related deaths. Most patients with ER+ metastatic breast cancer (MBC) undergo treatment with the estrogen receptor antagonist fulvestrant as standard of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10b4132d6b56eba42f1eb12d4ae2f62b
https://doi.org/10.1158/1541-7786.c.6545651.v1
https://doi.org/10.1158/1541-7786.c.6545651.v1
Autor:
Evelyn Aranda, Brandi Patrice Smith, Rithva Ramesh, Ayca Nazli Mogol, David J. Shapiro, Ozan Berk Imir, Zeynep Madak-Erdogan, Jenna Kathryn Lee, Qianying Zuo, Mrinali P. Kesavadas, Chengjian Mao, Drew Daly, John D. O’Neill, Yosef Landesman, Ashlie Santaliz-Casiano, Elif Tunc, Monika Ziogaite, Christopher J. Walker, Eylem Kulkoyluoglu Cotul, Ben Ho Park, Kevin Duong, Benita S. Katzenellenbogen, Elijah Odukoya
Publikováno v:
Cancers
Volume 12
Issue 9
Cancers, Vol 12, Iss 2397, p 2397 (2020)
Volume 12
Issue 9
Cancers, Vol 12, Iss 2397, p 2397 (2020)
The majority of breast cancer specific deaths in women with estrogen receptor positive (ER+) tumors occur due to metastases that are resistant to therapy. There is a critical need for novel therapeutic approaches to achieve tumor regression and/or ma